Pretreatment with hexamethonium (C6), a nonspecific nAChR antagonist, or methyllycaconitine (MLA), an α7nAChR antagonist, significantly reversed the suppressive effects of nicotine on weight loss, the DAS (nicotine: 3.0 ± 0.8, C6: 8.7 ± 1.1, MLA: 7.4 ± 1.2), the CDS (nicotine: 2.4 ± 0.4, C6: 5.1 ± 1.0, MLA: 4.9 ± 0.9), and MPO activity (nicotine: 2.3 ± 0.5, C6: 3.4 ± 0.5, MLA: 5.5 ± 1.2 kunits/gwwt) in OXZ colitis (Fig. 1C,D). This evidence concerns the gene MPO and colitis.